Mortality in Non-cystic Fibrosis Bronchiectasis

Mortality in Non-cystic Fibrosis Bronchiectasis: a Long-term Cohort Analysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01792427

Enrollment

253

Registered

2013-02-15

Start date

2006-06-30

Completion date

2012-12-31

Last updated

2013-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-cystic Fibrosis Bronchiectasis

Brief summary

In this study we analyzed the overall survival for all newly diagnosed patients with non-cystic fibrosis bronchiectasis from June 2006 onwards. The investigators wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa and evaluate the impact on survival of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin use and presence/development of pulmonary hypertension.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with clinically significant and radiologically proven bronchiectasis * Chest CT scan confirming the presence of bronchiectatic lesions and had symptoms of chronic productive cough * Bronchiectasis was deemed to be present if there was one or more of the following criteria: a bronchoarterial ratio greater than 1, lack of tapering of the bronchi and visualization of bronchi within 1 cm of costal or paravertebral pleura or abutting the mediastinal pleura

Exclusion criteria

* diagnosis of cystic fibrosis * underlying tumoral problem causing the bronchiectatic lesions (postradiotherapy, secondary immunodeficiency due to chemotherapy or postinfectious due to tumoral obstruction) * patients with asymptomatic traction bronchiectasis caused by interstitial lung disease

Design outcomes

Primary

Measure	Time frame
overall survival	6 years 4 months

Secondary

Measure	Time frame	Description
risk factor identification for NCFB	6 years 4 months	The investigators wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa.

Other

Measure	Time frame	Description
Identify cause of death	6 years 4 months	If death occurred, the patient file was reassessed to identify cause of death.
risk factor identification for the survival of NCFB	6 years 4 months	The investigators will evaluate the impact of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin use and presence/development of pulmonary hypertension on survival .

Countries

Belgium

Outcome results